J. Hong
8 Papers
J. Hong is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has co-authored 4 publications.
Chat about Author
Papers
646 Heterogeneity of cystic fibrosis transmembrane conductance regulator transcript expression levels in people with cystic fibrosis
Mark-André Freyberg,Matthew S. Bewig,Giovana B Bampi,Roman Rauscher,Jörg Große-Onnebrink,Sivagurunathan Sutharsan,J. Hong,Candela Manfredi,Eric J. Sorscher,Florian Stehling,I. Bobis,Manfred Ballmann,Zoya Ignatova +12 more
606 Focused clinical trials of modulator response for rare cystic fibrosis genotypes
G. Solomon,Shingo Suzuki,Heather Hathorne,Cristina Barillà,B. Wang,A. Rab,Candela Manfredi,Disha Joshi,John J. Brewington,Arlene A. Stecenko,W. Driggers,S. Bai,Elizabeth Hunter,A. Streby,J. Hong,Katherine Odem-Davis,Brian R. Davis,Eric J. Sorscher,R. Linnemann +18 more
385 Mechanisms by which cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection
Philip R. Tedbury,Candela Manfredi,Jillian Conway,Michael Horwath,Crystal M. McCracken,A. Sorscher,Steven Moreau,Ciara Wright,Caitlin E. Edwards,J. Brewer,Jeannette Guarner,Erika de Wit,Brittany Williamson,Yanwen Cheryl-lynn Ong,John D. Roback,David Alter,Frauke Degenhardt,Thore K. Karlsen,Andre Franke,Stefan G. Sarafianos,Eric J. Sorscher,J. Hong,Annette Ehrhardt +22 more
TL;DR: It is predicted that ELD607 treatment will people with CF by rebalancing Ca 2+ signaling in CF neutrophils and reducing inflammation, and it is shown that levels of angiotensin will be normal in CF primary epithelium, whereas transmembrane sermem5 efficiency will be low and levels of protease/anti-protease imbalance high.
280 Induced pluripotent stem cell–based airway epithelial platform for investigating personalized responses to CFTR modulators
Cristina Barillà,A. Rab,Shingo Suzuki,R. Bertrand,S. Winkler,S. Ponnaluri,Elizabeth Hunter,A. Streby,C. Driggers,B. Buehler,J. Hong,C. McNicholas,R. Linnemann,G. Solomon,A. Stecenko,Eric J. Sorscher,Brian R. Davis +16 more
TL;DR: Researchers developed an inhaled mRNA-based treatment using lipid nanoparticles to rescue CFTR function in patient-derived airway epithelial cells, achieving significant rescue in cells from individuals with unresponsive mutations, offering a potential treatment option for a significant fraction of people with cystic fibrosis.